Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

News provided by

Jan 20, 2014, 09:54 ET

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth

Summary

GBI Research, a leading business intelligence provider, has released its latest research report, "Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth". The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This growth is expected despite the generic erosion facing the leading brands, and is a consequence of new market entrants and a disease prevalence that continues to rise, albeit not at rates as high as have been seen in the past.

Some new, costly asthma therapies could be set to enter the asthma market, including GlaxoSmithKline's (GSK's) recently approved Relvar (fluticasone/vilanterol), and multiple monoclonal antibodies (mAbs). These include reslizumab, mepolizumab and lebrikizumab, which are being developed by Teva, GSK and Roche respectively.

The mAbs, in particular, have the potential to change the asthma treatment landscape, most notably with regards to severe forms of the disease. Although such therapy may only play the role of an alternative treatment in the asthma treatment algorithm, their ability to reduce exacerbation rates has strong clinical and commercial value.

Scope

The report assesses the current asthma market, and forecasts market trends to 2019, analyzing key drivers and barriers. The areas covered include the following -
- A disease introduction, which defines the disease, including symptoms, diagnosis and treatment
- Analysis of the landscape of the asthma market, including a comparison of the efficacy and safety of the most prominent brands
- Detailed analysis of the asthma pipeline, including, among other parameters, details of drug distribution by phase, molecule type and mechanism of action. The asthma clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as trends in clinical trial size and duration, and by mechanism of action. This section also includes single-product forecasts for the most promising pipeline drugs.
- An in-depth forecasting model for the asthma market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies.
- Analysis of strategic consolidations within the asthma indication, including co-development and licensing agreements
- An overview of the drivers and barriers for the asthma market

Reasons to buy

Primarily, the report will enable clients to establish a strong understanding of the asthma indication, helping to identify and understand market opportunities and the emerging competitive environment. It will also enable you to -
- Understand the asthma pipeline and the factors that indicate that it is becoming more innovative. This is highlighted by the presence of numerous biologics in the pipeline, which look set to have a major impact upon the asthma market.
- Observe detailed profiles for promising pipeline products, including revenue forecasts, and gain insights into how they are likely to compete in the market and who their main competitors will be.
- Follow the trends in asthma clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for asthma therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
- Observe the potential growth patterns expected for the asthma market over the forecast period, and identify which countries are expected to contribute the most to this growth.

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Introduction 9
2.2 Symptoms 9
2.3 Etiology 9
2.4 Pathophysiology 10
2.5 Diagnosis 10
2.6 Assessment of Disease Severity 11
2.7 Treatment 14
2.8 Treatment Algorithm 15
3 Marketed Products 17
3.1 Product Profiles 18
3.1.1 Advair Diskus (fluticasone and salmeterol) – GlaxoSmithKline 18
3.1.2 Symbicort (budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas Pharma Inc 19
3.1.3 Singulair (montelukast) – Merck & Co 19
3.1.4 Xolair (omalizumab) – Novartis and Genentech 20
3.1.5 Foradil (formoterol) – Novartis (Co-marketed by Novartis and Schering Corporation) 20
3.1.6 Dulera/Zenhale (mometasone/formoterol) – Merck & Co 21
3.1.7 Relvar/Breo – GlaxoSmithKline/Theravance 21
4 Asthma Pipeline 23
4.1 Overview 23
4.2 Mechanisms of Action in the Pipeline 26
4.3 Clinical Trials 29
4.3.1 Failure Rate 29
4.3.2 Clinical Trial Duration 34
4.3.3 Clinical Trial Size 37
4.3.4 Comparative Clinical Trial Metrics Analysis 40
4.4 Promising Pipeline Molecules 42
4.4.1 Reslizumab – Teva Pharmaceutical ltd 42
4.4.2 Mepolizumab - GlaxoSmithKline 44
4.4.3 Lebrikizumab – Roche/Genentech 46
4.4.4 Veramyst - GlaxoSmithKline 48
4.4.5 Andolast – Rottapharm Madaus 50
4.4.6 Spiriva (Tiotropium Bromide) – Boehringer Ingelheim 51
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 52
5 Market Forecast to 2019 58
5.1 Geographical Markets 58
5.1.1 Global Market 59
5.1.2 North America 62
5.1.3 Top Five Countries of Europe 65
5.1.4 Japan 69
5.2 Drivers and Barriers for the Asthma Therapeutics Market 71
5.2.1 Drivers 71
5.2.2 Barriers 72
6 Strategic Consolidations 73
6.1 Major Licensing Deals 73
6.2 Major Co-development Deals 81
7 Appendix 85
7.1 All Pipeline Drugs by Phase 85
7.1.1 Discovery 85
7.1.2 Preclinical 86
7.1.3 Phase I 89
7.1.4 Phase II 90
7.1.5 Phase III 92
7.1.6 Filed 92
7.1.7 Undisclosed 93
7.2 Market Forecast to 2019 93
7.2.1 Global 93
7.2.2 US 93
7.2.3 Canada 94
7.2.4 UK 94
7.2.5 France 94
7.2.6 Germany 95
7.2.7 Italy 95
7.2.8 Spain 95
7.2.9 Japan 96
7.3 References 96
7.3.1 References for Pipeline Heat Map 100
7.3.2 References for Marketed Heat Map 101
7.4 Market Definitions 101
7.5 Abbreviations 101
7.6 Methodology 102
7.7 Coverage 103
7.8 Secondary Research 103
7.9 Therapeutic Landscape 103
7.10 Epidemiology-Based Forecasting 104
7.10.1 Analogous Forecasting Methodology 104
7.11 Market Size by Geography 105
7.11.1 Forecasting Model for Therapeutic Areas 105
7.12 Geographical Landscape 106
7.13 Pipeline Analysis 106
7.14 Competitive Landscape 106
7.14.1 Expert Panel Validation 106
7.15 Contact Us 106
7.16 Disclaimer 106

List of Tables

Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 0–4 Years of Age 11
Table 2: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Children of 5–11 Years of Age 12
Table 3: Asthma Therapeutics Market, Global, Classification of Asthma Severity in Youths ? 12 Years of Age and Adults 13
Table 4: Management of Chronic Asthma 15
Table 5: Management of Acute Asthma 16
Table 6: Asthma Therapeutics Market, Global, Pipeline, Discovery, 2013 85
Table 7: Asthma Therapeutics Market, Global, Pipeline, Preclinical, 2013 86
Table 8: Asthma Therapeutics Market, Global, Pipeline, Phase I, 2013 89
Table 9: Asthma Therapeutics Market, Global, Pipeline, Phase II, 2013 90
Table 10: Asthma Therapeutics Market, Global, Pipeline, Phase III, 2013 92
Table 11: Asthma Therapeutics Market, Global, Pipeline, Filed, 2013 92
Table 12: Asthma Therapeutics Market, Global, Pipeline, Undisclosed, 2013 93
Table 13: Asthma, Global, Market Forecast, 2012–2019 93
Table 14: Asthma, US, Market Forecast, 2012–2019 93
Table 15: Asthma, Canada, Market Forecast, 2012–2019 94
Table 16: Asthma, UK, Market Forecast, 2012–2019 94
Table 17: Asthma, France, Market Forecast, 2012–2019 94
Table 18: Asthma, Germany, Market Forecast, 2012–2019 95
Table 19: Asthma, Italy, Market Forecast, 2012–2019 95
Table 20: Asthma, Spain, Market Forecast, 2012–2019 95
Table 21: Asthma, Japan, Market Forecast, 2012–2019 96

List of Figures

Figure 1: Asthma Therapeutics Market, Global, Pipeline, 2013 24
Figure 2: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, 2013 26
Figure 3: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase I, 2013 27
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase II, 2013 28
Figure 5: Asthma Therapeutics Market, Global, Pipeline by Mechanism of Action, Phase III, 2013 28
Figure 6: Asthma Therapeutics Market, Global, Clinical Trial Failure Rate, 2013 30
Figure 7: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase I, 2013 31
Figure 8: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase II, 2013 31
Figure 9: Asthma Therapeutics Market, Global, Clinical Trial Failure Rates by Mechanism of Action, Phase III, 2013 32
Figure 10: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration, 2013 34
Figure 11: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase I, 2013 35
Figure 12: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase II, 2013 35
Figure 13: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Mechanism, Phase III, 2013 36
Figure 14: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size, 2013 37
Figure 15: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase I, 2013 38
Figure 16: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase II, 2013 38
Figure 17: Asthma Therapeutics Market, Global, Pipeline, Clinical Trial Size by Mechanism, Phase III, 2013 39
Figure 18: Asthma Therapeutics Market, Global, Pipeline, Mechanism of Action Heat Map, 2012 41
Figure 19: Asthma Therapeutics Market, Global, Reslizumab Forecast ($m), 2014–2019 43
Figure 20: Asthma Therapeutics Market, Global, Mepolizumab Forecast ($m), 2015–2019 45
Figure 21: Asthma Therapeutics Market, Global, Lebrikizumab Forecast ($m), 2015–2019 47
Figure 22: Asthma Therapeutics Market, Global, Veramyst Forecast ($m), 2014–2019 49
Figure 23: Asthma Therapeutics Market, Global, Andolast Forecast ($m), 2015–2019 50
Figure 24: Asthma Therapeutics Market, Global, Tiotropium Bromide Forecast ($m), 2014–2019 52
Figure 25: Asthma Therapeutics Market, Global, Pipeline, Efficacy Heat Map, 2013 53
Figure 26: Asthma Therapeutics Market, Global, Pipeline, Safety Heat Map, 2013 54
Figure 27: Asthma Therapeutics Market, Global, Marketed Products, Safety and Efficacy Heat Map, 2013 55
Figure 28: Asthma Therapeutics Market, Global, Pipeline, Competitor Grid, 2013 56
Figure 29: Asthma Therapeutics Market, Global, Treatment Patterns, 2012–2019 59
Figure 30: Asthma Therapeutics Market, Global, Market Size, 2012–2019 60
Figure 31: Asthma Therapeutics Market, North America, Treatment Patterns, 2012–2019 62
Figure 32: Asthma Therapeutics Market, North America, Annual Cost of Treatment, 2012–2019 63
Figure 33: Asthma Therapeutics Market, North America, Market Size, 2012–2019 64
Figure 34: Asthma Therapeutics Market, Top Five EU Countries, Treatment Patterns, 2012–2019 65
Figure 35: Asthma Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019 67
Figure 36: Asthma Therapeutics Market, Top Five EU Countries, Market Size ($bn), 2012–2019 68
Figure 37: Asthma Therapeutics Market, Japan, Treatment Patterns and Annual Cost of Treatment, 2012–2019 69
Figure 38: Asthma Therapeutics Market, Japan, Market Size, 2012–2019 70
Figure 39: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013 73
Figure 40: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013 74
Figure 41: Asthma Therapeutics Market, Global, Major Licensing Deals, 2006–2013 75
Figure 42: Asthma Therapeutics Market, Global, Major Licensing Deals, Completed and Terminated 76
Figure 43: Asthma Therapeutics Market, Global, Major Licensing Deals by Phase and Molecule Type, 2006–2012 77
Figure 44: Asthma Therapeutics Market, Global, Major Licensing Deals, Mechanism of Action 78
Figure 45: Asthma Therapeutics Market, Global, Major Co-developments by Region and Value, 2006–2013 81
Figure 46: Asthma Therapeutics Market, Global, Major Co-developments by Year, 2006–2013 81
Figure 47: Asthma Therapeutics Market, Global, Major Co-developments by Phase, 2006–2013 82
Figure 48: Asthma Therapeutics Market, Global, Major Co-developments by Phase and Molecule Type, 2006–2013 83
Figure 49: Forecasting Model for Therapeutic Areas 105